Catalyst Wire Dossier Catalyst Wire Dossier

eftilagimod alfa

eftilagimod alfa · Immutep S.A.S.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for eftilagimod alfa, covering 2026-03-18 to 2026-03-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) [Phase 3]

See pricing